Ayaka Okamoto Selected Research

Small Interfering RNA (siRNA)

1/2023	Treatment of PTEN-Null Breast Cancer by a Synthetic Lethal Approach Involving PARP1 Gene Silencing.
1/2019	Design of a Novel PEGylated Liposomal Vector for Systemic Delivery of siRNA to Solid Tumors.
1/2019	Therapeutic Silencing of Centromere Protein X Ameliorates Hyperglycemia in Zebrafish and Mouse Models of Type 2 Diabetes Mellitus.
1/2018	Systemic Administration of siRNA with Anti-HB-EGF Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer.
4/2016	One-step encapsulation of siRNA between lipid-layers of multi-layer polycation liposomes by lipoplex freeze-thawing.
7/2014	Antibody-modified lipid nanoparticles for selective delivery of siRNA to tumors expressing membrane-anchored form of HB-EGF.
2/2014	Cell-penetrating peptide-conjugated lipid nanoparticles for siRNA delivery.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ayaka Okamoto Research Topics

Disease

9	Neoplasms (Cancer) 01/2023 - 01/2013
2	Triple Negative Breast Neoplasms 01/2023 - 01/2018
2	Breast Neoplasms (Breast Cancer) 10/2022 - 07/2014
1	Metaplasia 11/2021
1	Infections 11/2021
1	Polyps 11/2021
1	Hyperglycemia 01/2019
1	Type 2 Diabetes Mellitus (MODY) 01/2019
1	Carcinoma (Carcinomatosis) 01/2018
1	Fibrosarcoma 02/2014
1	Melanoma (Melanoma, Malignant) 02/2014

Drug/Important Bio-Agent (IBA)

7	Small Interfering RNA (siRNA)IBA 01/2023 - 02/2014
4	Liposomes (Liposome)IBA 01/2023 - 01/2013
3	Proteins (Proteins, Gene)FDA Link 11/2021 - 05/2014
3	Triethylenephosphoramide (TEPA)IBA 01/2016 - 01/2013
2	Heparin-binding EGF-like Growth Factor (HB-EGF)IBA 01/2018 - 07/2014
2	Epidermal Growth Factor (EGF)IBA 01/2018 - 07/2014
2	Lipid NanoparticlesIBA 01/2018 - 07/2014
2	alanyl-prolyl-arginyl-prolyl-glycineIBA 01/2016 - 05/2014
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2016 - 05/2014
2	tetraethylenepentamineIBA 01/2016 - 01/2013
1	TensinsIBA 01/2023
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2023
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2023
1	RNA (Ribonucleic Acid)IBA 01/2023
1	Doxycycline (Periostat)FDA LinkGeneric 10/2022
1	4-hydroxy-2-nonenal (4-hydroxynonenal)IBA 11/2021
1	8-Hydroxy-2'-DeoxyguanosineIBA 11/2021
1	diethylenetriamineIBA 01/2019
1	Insulin (Novolin)FDA Link 01/2019
1	DEET (DET)IBA 01/2019
1	MorpholinosIBA 01/2019
1	dioleoyl phosphateIBA 01/2019
1	Radioisotopes (Radionuclides)IBA 01/2018
1	Polo-Like Kinase 1IBA 01/2018
1	Peptides (Polypeptides)IBA 01/2016
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2016
1	Heparin (Liquaemin)FDA LinkGeneric 07/2014
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 07/2014
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 05/2014
1	Therapeutic UsesIBA 05/2014
1	enhanced green fluorescent proteinIBA 02/2014
1	6-chloro-2-(1-piperazinyl)pyrazine (CPP)IBA 02/2014
1	LuciferasesIBA 02/2014
1	dicetylphosphateIBA 01/2013
1	MicroRNAs (MicroRNA)IBA 01/2013

Therapy/Procedure

3	Intravenous Injections 01/2019 - 05/2014
3	Therapeutics 01/2016 - 01/2013
1	Drug Therapy (Chemotherapy) 01/2016